Zhejiang Supor Pharmaceuticals Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is RIVAROXABAN, with a corresponding US DMF Number 29439.
Remarkably, this DMF maintains an Active status since its submission on May 18, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of December 04, 2015, and payment made on August 18, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II